Fear & Greed Index Rises as U.S. Stocks Decline Sharply
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 09 2026
0mins
Source: Benzinga
- Deteriorating Market Sentiment: The CNN Money Fear & Greed Index recorded a reading of 26.7 on Friday, indicating a persistent state of 'Fear' in the market, down from 28.3 previously, reflecting investor anxiety about future market conditions.
- Significant Stock Market Decline: The Dow Jones dropped over 450 points to close at 47,501.55, while the S&P 500 fell 1.33% to 6,740.02, and the Nasdaq Composite declined 1.59%, showcasing overall market weakness and investor pessimism.
- Weak Economic Data: U.S. retail sales fell by 0.2% month-over-month in January, missing the market estimate of a 0.3% decline, and the nonfarm payrolls decreased by 92,000 in February 2026, with the unemployment rate rising to 4.4%, indicating heightened risks of economic slowdown.
- Oil Price Surge Risks: Qatar's energy minister warned that oil prices could surge past $150 if the Strait of Hormuz were to close completely, with crude prices rallying nearly 35% this week, marking the largest weekly gain in commodity trading history, which could have profound implications for the global economy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRVL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRVL
Wall Street analysts forecast MRVL stock price to fall
30 Analyst Rating
22 Buy
8 Hold
0 Sell
Moderate Buy
Current: 230.700
Low
85.00
Averages
120.12
High
156.00
Current: 230.700
Low
85.00
Averages
120.12
High
156.00
About MRVL
Marvell Technology, Inc. together with its consolidated subsidiaries, is a supplier of data infrastructure semiconductor solutions, spanning the data center core to network edge. It is engaged in the design, development and sale of integrated circuits. Its product offerings include custom application-specific integrated circuits (ASICs), interconnects, ethernet solutions, fiber channel adapters, processors and storage controllers. In addition, it is also developing Ultra Accelerator LinkTM (UALinkTM) switches and ethernet for scale-up networking (ESUN) switches for the emerging scale-out artificial intelligence market. Its solutions integrate multiple analogs, mixed-signal and digital intellectual property components incorporating hardware, firmware and software technologies and its system knowledge to provide its customers with integrated solutions for their end products. It designs and manufactures photonic integrated circuits for ultra-high-bandwidth and low-power applications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Marvell Technology: Pathway to a Trillion-Dollar Valuation
- Strong Data Center Demand: In Q1 FY2027, Marvell Technology reported a 28% year-over-year revenue increase to nearly $2.4 billion, with operating cash flow reaching a record $639 million, indicating robust performance in the data center market, and expects FY2027 revenue to hit $11.5 billion, up 40% year-over-year.
- Custom Chip Growth Potential: Marvell anticipates its custom chip business will exceed $10 billion in revenue by FY2029, driven by rising demand for interconnects, switches, and custom chips that enhance data processing efficiency for large AI systems, with interconnect product revenue expected to grow 70% year-over-year in FY2027.
- Nvidia Investment Boosts Credibility: Nvidia's $2 billion investment not only adds credibility to Marvell's growth narrative but also facilitates closer integration of Marvell's custom AI chips with Nvidia's AI infrastructure, aiding next-generation AI systems in overcoming data transfer speed and efficiency limitations.
- Acquisition Expands Technical Capabilities: Marvell's acquisitions of Celestial AI and XConn enhance its capabilities in optical interconnect and switching technologies, which will facilitate higher bandwidth, lower power usage, and reduced latency in data transmission across large AI networks, further solidifying its market position.
See More
Tom Gardner's Five Long-Term Investment Picks
- Portfolio Strategy: Tom Gardner advocates for individual investors to hold at least fifty stocks to navigate the disruptions caused by AI, emphasizing the importance of diversification to mitigate risks and enhance long-term return potential in today's richly priced market.
- Cautious Investment Picks: Gardner's three cautious picks include Cisco Systems, MSCI, and Kingstone Companies, with Cisco boasting $13 billion in free cash flow and double-digit return on assets, while Kingstone has impressively risen from under $1 to $15 per share under strong leadership, showcasing effective management capabilities.
- Moderate Risk Investment: Marvell Technology is identified as a moderate risk option, expected to generate $6 billion in free cash flow in the coming years, with its chips playing a crucial role in rapid data transfer between data centers, potentially positioning it as the next trillion-dollar company.
- Aggressive Investment Opportunity: BillionToOne is classified as an aggressive investment, focusing on advanced genetic testing technologies, with founders possessing strong scientific backgrounds dedicated to identifying minute signals in complex DNA, demonstrating significant market potential and a mission-driven business model.
See More
Tom Gardner's Five Long-Term Stock Picks
- Portfolio Recommendation: Tom Gardner advises that the average investor should own at least fifty stocks to navigate market uncertainties, a viewpoint supported by Peter Lynch's success, emphasizing the importance of diversification in investment strategies.
- AI Transforming Research: Gardner highlights that AI agents are reshaping the investment research landscape, with The Motley Fool making substantial investments in AI scoring systems to identify long-term investment opportunities, showcasing the company's forward-thinking approach to future investment trends.
- Stock Picks: Gardner recommends five stocks, including Cisco Systems (CSCO), MSCI, Kingstone Companies, Marvell Technology, and BillionToOne, spanning a risk spectrum from cautious to aggressive, aimed at helping investors build a diversified long-term portfolio.
- Market Environment Analysis: In the current richly valued market, Gardner suggests that investors adopt cautious and moderate investment strategies, particularly when large IPOs are frequent, indicating a potentially high-risk market environment.
See More
Three High-Potential Stocks: Abivax, Krystal Biotech, and Marvell
- Strong Performance of Abivax: Abivax's stock has surged over 1,500% in the past 12 months, primarily due to the impressive efficacy of its candidate drug obefazimod for ulcerative colitis, with an expected application for approval by the end of 2026 that could significantly enhance its market share.
- Financial Growth of Krystal Biotech: Krystal Biotech's Vyjuvek generated $116.4 million in revenue in Q1, a 32% increase year-over-year, with a net profit of $55.9 million, up 56.5%, indicating strong demand and profitability in the rare disease market.
- Market Demand for Marvell Technology: Marvell Technology reported a record net revenue of $2.4 billion in Q1 of fiscal 2027, up 28% year-over-year, with 76% of revenue from its data center segment, and is expected to benefit from increasing demand for ASICs as AI infrastructure spending grows.
- Future Growth Potential: All three companies exhibit strong growth potential, with Abivax and Krystal Biotech driving future performance through innovative drug development, while Marvell is well-positioned to capitalize on the expansion of the AI market, potentially delivering market-beating returns.
See More
Abivax, Krystal Biotech, and Marvell's Market Potential
- Abivax's Clinical Progress: Abivax's shares have surged over 1,500% in the past 12 months, driven by strong efficacy results of its candidate obefazimod for ulcerative colitis, with an application for approval expected by the end of 2026, potentially carving out a niche in a competitive market.
- Krystal Biotech's Financial Performance: In Q1, Krystal Biotech reported revenue of $116.4 million, a 32% increase year-over-year, with a net profit of $55.9 million, up 56.5%, indicating strong market demand and profitability in treating rare diseases, with further growth anticipated.
- Marvell's Market Demand: Marvell Technology achieved a record net revenue of $2.4 billion in Q1 of fiscal 2027, up 28% year-over-year, with 76% of revenue from its data center segment, and as AI infrastructure spending rises, sales and earnings are expected to continue growing.
- Optimistic Industry Outlook: All three companies exhibit strong growth potential in their respective fields, with Abivax and Krystal Biotech's innovative drugs and Marvell's custom chips likely to deliver significant market returns in the coming years, attracting investor interest.
See More
US Stocks Close Lower as Chipmakers Weigh on Market
- Market Decline: On Tuesday, the S&P 500 index fell by 0.45%, the Dow Jones Industrial Average dropped by 0.25%, and the Nasdaq 100 index decreased by 1.77%, indicating a broader market decline under pressure from a selloff in chipmakers, reflecting investor concerns over high valuations.
- Samsung's Earnings Disappointment: Despite Samsung Electronics reporting a 19-fold profit surge, its stock plummeted over 8% in South Korea, suggesting market skepticism regarding the future profitability of the semiconductor sector, which could impact investor confidence in related companies.
- Geopolitical Risks Heightened: Crude oil prices surged to a 1.5-week high due to attacks on shipping in the Strait of Hormuz, raising inflation expectations and pushing bond yields higher, with the 10-year T-note yield reaching a 3.5-week high of 4.54%, adding uncertainty to the market.
- Strength in Software Stocks: Despite the overall market pressure, strong performance in software stocks indicates a rotation of funds into other sectors, with companies like Workday seeing stock price increases of over 4%, providing some support for the market.
See More
Marvell Technology: Pathway to a Trillion-Dollar Valuation
- Strong Data Center Demand: In Q1 FY2027, Marvell Technology reported a 28% year-over-year revenue increase to nearly $2.4 billion, with operating cash flow reaching a record $639 million, indicating robust performance in the data center market, and expects FY2027 revenue to hit $11.5 billion, up 40% year-over-year.
- Custom Chip Growth Potential: Marvell anticipates its custom chip business will exceed $10 billion in revenue by FY2029, driven by rising demand for interconnects, switches, and custom chips that enhance data processing efficiency for large AI systems, with interconnect product revenue expected to grow 70% year-over-year in FY2027.
- Nvidia Investment Boosts Credibility: Nvidia's $2 billion investment not only adds credibility to Marvell's growth narrative but also facilitates closer integration of Marvell's custom AI chips with Nvidia's AI infrastructure, aiding next-generation AI systems in overcoming data transfer speed and efficiency limitations.
- Acquisition Expands Technical Capabilities: Marvell's acquisitions of Celestial AI and XConn enhance its capabilities in optical interconnect and switching technologies, which will facilitate higher bandwidth, lower power usage, and reduced latency in data transmission across large AI networks, further solidifying its market position.
See More
Tom Gardner's Five Long-Term Investment Picks
- Portfolio Strategy: Tom Gardner advocates for individual investors to hold at least fifty stocks to navigate the disruptions caused by AI, emphasizing the importance of diversification to mitigate risks and enhance long-term return potential in today's richly priced market.
- Cautious Investment Picks: Gardner's three cautious picks include Cisco Systems, MSCI, and Kingstone Companies, with Cisco boasting $13 billion in free cash flow and double-digit return on assets, while Kingstone has impressively risen from under $1 to $15 per share under strong leadership, showcasing effective management capabilities.
- Moderate Risk Investment: Marvell Technology is identified as a moderate risk option, expected to generate $6 billion in free cash flow in the coming years, with its chips playing a crucial role in rapid data transfer between data centers, potentially positioning it as the next trillion-dollar company.
- Aggressive Investment Opportunity: BillionToOne is classified as an aggressive investment, focusing on advanced genetic testing technologies, with founders possessing strong scientific backgrounds dedicated to identifying minute signals in complex DNA, demonstrating significant market potential and a mission-driven business model.
See More
Tom Gardner's Five Long-Term Stock Picks
- Portfolio Recommendation: Tom Gardner advises that the average investor should own at least fifty stocks to navigate market uncertainties, a viewpoint supported by Peter Lynch's success, emphasizing the importance of diversification in investment strategies.
- AI Transforming Research: Gardner highlights that AI agents are reshaping the investment research landscape, with The Motley Fool making substantial investments in AI scoring systems to identify long-term investment opportunities, showcasing the company's forward-thinking approach to future investment trends.
- Stock Picks: Gardner recommends five stocks, including Cisco Systems (CSCO), MSCI, Kingstone Companies, Marvell Technology, and BillionToOne, spanning a risk spectrum from cautious to aggressive, aimed at helping investors build a diversified long-term portfolio.
- Market Environment Analysis: In the current richly valued market, Gardner suggests that investors adopt cautious and moderate investment strategies, particularly when large IPOs are frequent, indicating a potentially high-risk market environment.
See More
Three High-Potential Stocks: Abivax, Krystal Biotech, and Marvell
- Strong Performance of Abivax: Abivax's stock has surged over 1,500% in the past 12 months, primarily due to the impressive efficacy of its candidate drug obefazimod for ulcerative colitis, with an expected application for approval by the end of 2026 that could significantly enhance its market share.
- Financial Growth of Krystal Biotech: Krystal Biotech's Vyjuvek generated $116.4 million in revenue in Q1, a 32% increase year-over-year, with a net profit of $55.9 million, up 56.5%, indicating strong demand and profitability in the rare disease market.
- Market Demand for Marvell Technology: Marvell Technology reported a record net revenue of $2.4 billion in Q1 of fiscal 2027, up 28% year-over-year, with 76% of revenue from its data center segment, and is expected to benefit from increasing demand for ASICs as AI infrastructure spending grows.
- Future Growth Potential: All three companies exhibit strong growth potential, with Abivax and Krystal Biotech driving future performance through innovative drug development, while Marvell is well-positioned to capitalize on the expansion of the AI market, potentially delivering market-beating returns.
See More
Abivax, Krystal Biotech, and Marvell's Market Potential
- Abivax's Clinical Progress: Abivax's shares have surged over 1,500% in the past 12 months, driven by strong efficacy results of its candidate obefazimod for ulcerative colitis, with an application for approval expected by the end of 2026, potentially carving out a niche in a competitive market.
- Krystal Biotech's Financial Performance: In Q1, Krystal Biotech reported revenue of $116.4 million, a 32% increase year-over-year, with a net profit of $55.9 million, up 56.5%, indicating strong market demand and profitability in treating rare diseases, with further growth anticipated.
- Marvell's Market Demand: Marvell Technology achieved a record net revenue of $2.4 billion in Q1 of fiscal 2027, up 28% year-over-year, with 76% of revenue from its data center segment, and as AI infrastructure spending rises, sales and earnings are expected to continue growing.
- Optimistic Industry Outlook: All three companies exhibit strong growth potential in their respective fields, with Abivax and Krystal Biotech's innovative drugs and Marvell's custom chips likely to deliver significant market returns in the coming years, attracting investor interest.
See More
US Stocks Close Lower as Chipmakers Weigh on Market
- Market Decline: On Tuesday, the S&P 500 index fell by 0.45%, the Dow Jones Industrial Average dropped by 0.25%, and the Nasdaq 100 index decreased by 1.77%, indicating a broader market decline under pressure from a selloff in chipmakers, reflecting investor concerns over high valuations.
- Samsung's Earnings Disappointment: Despite Samsung Electronics reporting a 19-fold profit surge, its stock plummeted over 8% in South Korea, suggesting market skepticism regarding the future profitability of the semiconductor sector, which could impact investor confidence in related companies.
- Geopolitical Risks Heightened: Crude oil prices surged to a 1.5-week high due to attacks on shipping in the Strait of Hormuz, raising inflation expectations and pushing bond yields higher, with the 10-year T-note yield reaching a 3.5-week high of 4.54%, adding uncertainty to the market.
- Strength in Software Stocks: Despite the overall market pressure, strong performance in software stocks indicates a rotation of funds into other sectors, with companies like Workday seeing stock price increases of over 4%, providing some support for the market.
See More
